Treatment with a BTK inhibitor has been shown to yield good depth and duration of response in patients with chronic lymphocytic leukemia, regardless of TP53 status. READ MORE
From December 9-12, the American Society of Hematology will be hosting its Annual Meeting and Exposition in Atlanta, Georgia. The meeting will provide an opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology as well as to network with top minds in the field.
Treatment with a BTK inhibitor has been shown to yield good depth and duration of response in patients with chronic lymphocytic leukemia, regardless of TP53 status.
Research presented at the 2018 BMT Tandem Meetings showed that potential role of immune checkpoint inhibitors in the post-transplant setting for patients with relapsed or large B-cell lymphomas.
A study to be presented at the BMT Tandem Meetings found no difference in OS for patients aged 55-64 years compared with those aged 65 years and older with non-Hodgkin lymphoma who underwent alloHCT.
Survival outcomes may be worse for patients with ALL living in intermediate and high socioeconomically deprived areas as well as for those treated in hospitals with lower volumes of patients.
The National Comprehensive Cancer Network updated their induction and consolidation treatment recommendations for low-risk and high-risk acute myeloid leukemia.